A6

presence of both GM moieties and is a function of the length of the linker. GMD-4c may selectively interact with HER-kinase heterodimers, but it is also possible that it preferentially interacts with different hsp90 family members than GM.

On Page 9 of the specification, please replace the partial paragraph starting on line 1 as follows:

A7

100% dimethylsulfoxide (DMSO) and stored at -20°C prior to use in preparation of the geldanamycin derivatives of Fig. 2. The GM analogs were prepared according to the procedure depicted in Fig. 1, which is modified from the method of Schnur et al., *J. Med. Chem.* 38, 3813-3820 (1995). Briefly, the geldanamycin dimers (GMDs) were prepared by treatment of GM with 0.5 eq. of the appropriate diamine in DMSO. The ansa ring-opened GMDs (GMD-a and GMD-aa) were prepared by methanolysis (NaOMe/MeOH) of the GMD-4c. GM-quinone was synthesized by first treating GM with excess 1,4-diamobutane, then addition of 2-methoxy-1-hydroxymethylquinone.

In the Figures:

Please replace figures 1 and 2 with the enclosed replacement sheets.

In the claims:

Please cancel claims 3-5 and 8-11 and amend claims 6, 12 and 13 to read as follows:

6. (amended) The chemical compound of claim [5] 2, wherein the linker has a length of 4 to 7 carbon atoms.

12. (amended) A method for destruction of cells expressing a HER-family tyrosine kinase, comprising administering to the cells a chemical compound [according to any of claims 1-11] comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with

which ansamycin antibiotics bind, said binding moieties being connected to one another by a linker.

13. (amended) A method for treating cancer in a patient[s] suffering from cancer, comprising administering to the patient a therapeutic composition comprising a chemical compound [according to any of claims 1-11] comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with which ansamycin antibiotics bind, said binding moieties being connected to one another by a linker.

Please add claims 15-17 as follows:

15. The method according to claim 13, wherein at least one of the hsp-binding moieties is an ansamycin antibiotic.

16. The method according to claim 15, wherein the linker has a length of 4 to 7 carbon atoms.

17. The method according to claim 16, wherein the linker has a length of 4 carbon atoms.

REMARKS

This application is a continuation of PCT/US00/09512. In the International Preliminary Examination Report issued by the IPEA/US the Examiner indicated that claims 3-7 and 9-14 met the requirements of PCT Article 33(2)-(4). These claims are being pursued in the a concurrently filed. The present application is directed to the subject matter which was not considered in the PCT application.